{"name":"Hvivo","slug":"hvivo","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"G-004","genericName":"G-004","slug":"g-004","indication":"Type 2 diabetes","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Experimental: Protesomal Vaccine 1 x 30 µg","genericName":"Experimental: Protesomal Vaccine 1 x 30 µg","slug":"experimental-protesomal-vaccine-1-x-30-g","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"G-004","genericName":"G-004","slug":"g-004","phase":"phase_2","mechanism":"G-004 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Experimental: Protesomal Vaccine 1 x 30 µg","genericName":"Experimental: Protesomal Vaccine 1 x 30 µg","slug":"experimental-protesomal-vaccine-1-x-30-g","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQbDNLeEtjMDBoMHNoRnNPUHNueFhjYWNYbFpScjY2UXN5cXVUbFlwa2tJeUdaQkhrSGNBYmpXUXB2aEViQlBBbm45MVc4ci1lbTlpZlZBMzZKN3JnX0VJTXQwN1RJa1ZUcG4xSTBzeC10d3V4dURibGVldTY4anV3djhGRE1SbkpMWWhDZXEwUTRHaHFoVld6NmFEcWtpazVRcGFmRy1OVEtJcUNNdUZzZw?oc=5","date":"2026-01-10","type":"pipeline","source":"Share Talk","summary":"Six Biotechs to Watch in 2026: Breakthroughs, Setbacks, and Big Turning Points Ahead - Share Talk","headline":"Six Biotechs to Watch in 2026: Breakthroughs, Setbacks, and Big Turning Points Ahead","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE9FaE9jT1BUQTUxM2dWdmZVQ3ZSeVJkWHVKZktfM3lWSVdrMkJMbnhYLXQ1bnIzdVFoTHVtV3E2eGphZXNBVldWVHJrRVNDUUhvSTg1bHl1Q0VlbkZkLUk4TVNEQV9wOUNhTmcycWlOcw?oc=5","date":"2025-12-17","type":"pipeline","source":"pharmaphorum","summary":"Unlocking the future of obesity treatment - pharmaphorum","headline":"Unlocking the future of obesity treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPMTdtVFktZFZ6SWZiZjZndmZYWHk4a1RSSjJMN1dKVS0tT3ZEaWljSDAyRkVhUXd1NGdRZlR0bTktTHJRTVhnSHdmZDNUblZYdU9LX25yX3U3OE1uMkUyUENwRkZSdk44T3p0aFM0Zkp1YUNPTEVPcUluMHF3dUFHOXNIa1J4NTVJaVVEcDBJWnUwMEVJUDBBQ3I0ZVNPcGtmSURNRg?oc=5","date":"2025-12-12","type":"pipeline","source":"Proactive financial news","summary":"Broker backs hVIVO 2026 rebound - Proactive financial news","headline":"Broker backs hVIVO 2026 rebound","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNMmRuVUQzVmI4OExvVGUzQmdna3c5XzQ2QmNCeGVKck9OdXB3REMtcG42bmh4WHg3b0xTV09aRW9KM1ItRU4yTHBqTEotc0FsTVlORVFQcjB6TGxwQmRualJvTmpvWTVUX21wOFczVEdyZlFtTFowbkw0ZUZjZE8yaGR1bXB4SmZRVU5hZl9nQmhCbFE?oc=5","date":"2025-11-27","type":"trial","source":"PharmaTimes","summary":"MSD to acquire Cidara after positive phase 2b trial results - PharmaTimes","headline":"MSD to acquire Cidara after positive phase 2b trial results","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFBfMy1ZVUNHWkZKVUlKZjZDaVpORzA1X3RNM3NRbGNfSTR4WFotdm54TkRPRkNzbXdIMnNXZUUwY2NnY3BvUjFDR01QM1A1RTI1WTZsZkhkWk5FN2ZtOWxBQVFzb3dRM2JYOG1IcklfUXlyaVpiTHJuQzJjenRWMTg?oc=5","date":"2025-09-23","type":"earnings","source":"Business Post","summary":"Hvivo suffers half-year revenue slump - Business Post","headline":"Hvivo suffers half-year revenue slump","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQLUpKaVlQQ0pkaFdyMnZCaWxKS3FhMGtuZ000Y3pNYUJWMUU2Q2ZqYWFOTTNqWVdmZDEwa2J0RDlnRGZlbHNaTkJuTEY0WWhXTGRaQjBveUhHdzhUbHBHemgzdzVHZERpTlNpX3RxM0dGeTUzc1doOFJPMjRIYk1uX3l2WmlGV29jQ0p5STBoU2tyeVE?oc=5","date":"2025-09-03","type":"pipeline","source":"Pharmafile","summary":"Shaun Chilton appointed as hVIVO Non-Executive Chair - Pharmafile","headline":"Shaun Chilton appointed as hVIVO Non-Executive Chair","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxORHlDRXRQZTgtWVZZcktyUjZGRU5pNV9TeHlUSmZrTTExb1ltN3AtdlBzWUhkSUtaamJFQlNJc1kzb0xIeTRnc1hKRklpN04yMEdBYUduSXN6bmcxb0hfZzlyc1JtcXZFdWY1RGlKbURzMXBBM1FGSkJEcXVUVDB6dHJVeEM5ZUtfdHZPbFNKSm4xLW5IYWdRbFNZMkZPQXozRjk4?oc=5","date":"2025-07-22","type":"earnings","source":"The Irish Times","summary":"Hvivo revenue falls as pharma market uncertainty hits - The Irish Times","headline":"Hvivo revenue falls as pharma market uncertainty hits","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOU1lJMzJRaEdQWElrbDlWU2s0bTJxcmJTclFRdG1pajdxdXp5NlJUS0VEeEZHa21HSlowVzEycW81NmwxdGhNLUtuckF1ZWVQenljQ3c0ZmVHUUJ5N2V3Tnh4RFVZU1RlbW9UcnhCUzM0dzA4U3l6RDBDa05ISWZhakZWRzF4a05UazMwUVZJVXpWVzM1MDlUM3dn?oc=5","date":"2025-06-30","type":"trial","source":"PharmaTimes","summary":"Cidara and hVIVO report positive results in flu prevention study - PharmaTimes","headline":"Cidara and hVIVO report positive results in flu prevention study","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxNeXNuSzhxVlIwaFZXdGZBMkZ1bUs5Ul9UNmRJWWl3VTl1alJ4YUZkdTNvb1dLcEJKeHQ0QWUxZ1pCWjltMlp0ZDJMT1ByNmU3ZmxtZzRyRVlRZWsxclRaOGI4bkdGNWZFQW5Pak9RdDBTdTNRakVzQVh4Qy1yYW40b1duazAxU0JYalNLOXZDNU9xMmdXNmp6VmlNT0ZjZEd3NzRRVm9MN1dUejhqSFhwQzNTZkJrMnE4eWVCU3pfNDYtMFhsN2hMbk5vWDZNRkU1Q3hmMXhpTVhmb1U4MXpCdldaS3o1OUEyREo3bGQyMGNuY29zWTBzSEhfbjlSRk9JaWNUYWw1LUU?oc=5","date":"2025-06-30","type":"pipeline","source":"Proactive Investors","summary":"Incanthera, Faron Pharmaceuticals, hVIVO, Powerhouse Energy, CleanTech Lithium, ACG Metals - Small Cap Snapshot - Proactive Investors","headline":"Incanthera, Faron Pharmaceuticals, hVIVO, Powerhouse Energy, CleanTech Lithium, ACG Metals - Small Cap Snapshot","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxPM1VjeVQyZlBCSHhIN0MyNEN1Zk1hVWRveUFRUmwtZW02YVdYUUR3eDRvamJ5Vndxb3lMMFIzZlBsSnNvQUtlR0o3d0dQWnZNUE5FZzhPOVVwS2VEcGhza1U1SHo2NGI3WDBsMjg1T0ZTN3lJU0hZVjNjU20zQkJkZXBCd3JQVkxFa1NBb0VEY19YcXpBOVRhZUgxVHZoOXl2eFFHY0ZZOU1RWHJVWGxYVVhyQ0ZITEgxSGpUeGloVzJFczRGTm9zWVZfSnRJVUVpUm9LdFNR?oc=5","date":"2025-01-27","type":"regulatory","source":"BioSpace","summary":"ILiAD and hVIVO Sign LOI for Pivotal Phase 3 Trial of BPZE1 Pertussis Vaccine Following FDA Meeting - BioSpace","headline":"ILiAD and hVIVO Sign LOI for Pivotal Phase 3 Trial of BPZE1 Pertussis Vaccine Following FDA Meeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNeXZkWktHY3Fjc0RpWF9FbkhkOVJzSWNtVEJNYkd5LUIwdDdmZkxzbEMzRFk3NkFrekhuTmpGcVVLdHFZSHpoazIwTDFfYnVUZUdPQTRha3dWTU82aG1YTVRNZ2JrRWdlREJBUzFLVjloczBhM0dybUxNcWNWQWtObjNnZTlndHVpamk0Wm1xTi1NNlBGZmV1Q1VYVHZ3WFl3SjNjcmdqYw?oc=5","date":"2024-07-18","type":"pipeline","source":"Pharmaceutical Technology","summary":"Inside Canary Wharf’s infectious disease testing facility - Pharmaceutical Technology","headline":"Inside Canary Wharf’s infectious disease testing facility","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNRTM0RzRpNm9BLXpzRHdOczdqMzNkVWNBcGVJYXF4aUk0TXdYV1VzSUpXQUlhdDZtQ3RMRzNXQ1VWc1BYZ2s0Y29GQk9ZVVZwREtfbHRRMmsyWk00RjdCZjMtRDg5OWhjM1BXU2tMU09nQzU3djg4N25uZ3V0TjR6bFV2MjB6Y09NNVNxbU1MNW9fUQ?oc=5","date":"2023-12-13","type":"trial","source":"Fierce Biotech","summary":"British CRO hVIVO reels in £16.8M clinical trial deal for RSV drug - Fierce Biotech","headline":"British CRO hVIVO reels in £16.8M clinical trial deal for RSV drug","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_1":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}